PRESENTATION OF EUROPEAN PATIENTS' FORUM AND WAYS OF COLLABORATION

Valentina Strammiello
Programme Manager

Wednesday 8 November 2017
BioMed Alliance General Annual Meeting
Brussels, Belgium








About EPF



- European Patients' Forum
 - Independent & non-governmental
 - Umbrella organisation
 - Active since 2003
 - EU patients' voice
- Our members
 - 74 patient Umbrella groups
 - EU disease specific organisations &
 - National patient coalitions



Mission and vision



Our Vision:

All patients in the EU have equitable access to high quality, patient-centred health and social care.





Our Mission:

To ensure that the patient community drives health policies and programmes that affect them.

Our Strategic Goals





Health Literacy



Patient Empowerment



Healthcare Access and Quality



Patient involvement



Sustainable Patients'
Organisations



Non-discrimination

Evolution of EPF activities 2003-2017



Strengthening Patients' voice in the EU







Evolution from 1 to 3 "pillars"

EUPATI: An unprecedented collaboration



Collaboration between: Patient organisations, academia, health NGOs, pharmaceutical industry

- ► <u>IMI-EUPATI</u>: Funded by IMI (PPP between EC and EFPIA), ran for 5 years from Feb 2012 Jan 2017, Consortium of 30 + members led by EPF
- ▶ <u>EUPATI as current EPF programme</u>: continuation of Patient Expert Course, along with support for ENPs and expansion of IT and capacity building tools for patients

EUPATI develops and disseminates objective, credible, correct and upto-date information on medicines R&D in 7 European languages (3 more on the way!).

competencies and capacity among patients and public to get involved.



EUPATI facilitates patient involvement in R&D to
support academia,
industry, authorities and
ethics committees.

EUPATI: Three audiences





EUPATI Patient Expert Training Course for expert patients



12.000

English French

Polish Italian

Russian

EUPATI Internet Library

EUPATI Fellows are influencers and leaders



Role	Before Course	EUPATI	Post Course
Member of patient organisation, not actively involved	17%		2%
Active role in a patient organisation	62%		71%
Leadership role in a patient organisation	62%		71%
Employee of a patient organisation	25%		23%
Volunteer role in a patient organisation	60%		67%
Presenting at conferences, workshops etc.	63%		83%
Advising a pharmaceutical company	13%		44%
Advising a regulatory agency	21%		42%
Advising a reimbursement agency	4%		8%

Source: The EUPATI Fellow Experience Poll, December 2016, 52 respondents (83 Fellows)

Patient engagement in the life cycle of medicines-1



ADAPT-SMART and Medicines Adaptive Pathways to Patients (MAPPs)

The current drug development paradigm is challenged by numerous factors:

- ✓ Growing patient demand for quicker access to new/ innovative drug
- ✓ Increased fragmentation of treatment populations
- ✓ Reduced healthcare budget and rising payer influence
- ✓ Pressure on pharma/investors to ensure sustainable drug provision and an R&D model



ADAPT-SMART is an Innovative Medicines Initiative (IMI) funded project that seeks to address the above by establishing a neutral platform for enabling MAPPs related activities within the consortium and with all relevant stakeholders.

Patient engagement in the life cycle of medicines- 2



Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER)

PREFER is a five year project that has received funding from the Innovative Medicines Initiative and receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

PREFER aims to establish recommendations to support development of guidelines for industry, regulatory authorities, HTA bodies, and payers



on how and when to include patient preferences on benefits and risks of medical products.

Upcoming work on Patient Engagement -3



EPF works with key stakeholders aiming to enable and enhance meaningful and sustainable patient engagement in the medicines lifecycle, with focus on three key decision points:

- 1. R&D prioritisation,
- 2. Design of clinical trials,
- 3. Early dialogue between regulators and HTA bodies.

Key actions:

- Respond to the evolution of medicine development and new opportunities and expectations for more effective engagement,
- \circ Address ethics and added value of engagement,
- Contribute to increasing the understanding and appreciation of the added value of patient engagement by providing consensus-based recommendations and solutions on how to join up and 'mainstream' current disjointed engagement practices.



Patient Engagement in the body politic of IMI




Four key principles of Patient Engagement



Patient Engagement



Mainstreaming Patient Engagement



Recommendations for Patient Engagement in Research



- Information
- Education
- Systematic approach to PE to build
 - -Tools
 - Infrastructure
 - -TRUST



Conclusions



Take home messages for you

- ✓ Patient engagement no longer an optional but a strategic imperative to enhance health research and lead to better outcomes for patients
- ✓ EPF is ready and able to collaborate with the BIOMEDICAL Alliance to help to achieve this



THANK YOU FOR YOUR ATTENTION!

Follow the campaign on Social Media!

#ACCESS2030







/eupatient



eu-patient.eu/blog

More information www.eu-patient.eu info@eu-patient.eu



